Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib Improves OS in BRAF V600–Mutated Advanced Melanoma
Source: OncLive, February 2022
Frontline administration of the checkpoint inhibitors ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted agents dabrafenib plus trametinib improved overall survival (OS) in patients with BRAF V600–mutant melanoma vs the reverse sequence of combinations, according to data from the phase 3 DREAMseq trial (NCT02224781) presented during the ASCO Virtual Plenary Series.1
At a median follow-up of 27.7 months, patients who received the combination of ipilimumab plus nivolumab first experienced a 2-year OS rate of 72% (95% CI, 62%-79%) vs 52% (95% CI, 42%-60%) in those who were given dabrafenib/trametinib first; this translated to a 20% difference (P = .0095).
“Although at 59% information, the protocol-specified end point had not been met. The data safety monitoring committee felt that there was a clinically meaningful difference in OS and recommended that the study be closed to accrual,” lead investigator Michael B. Atkins, MD, stated in a presentation on the data. “Patients on first-line dabrafenib and trametinib were given the option to switch to…ipilimumab and nivolumab without the need for disease progression.”
READ THE ORIGINAL FULL ARTICLE